<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135967</url>
  </required_header>
  <id_info>
    <org_study_id>RUNMN02</org_study_id>
    <nct_id>NCT00135967</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil in Membranous Nephropathy</brief_title>
  <official_title>Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for
      end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a
      treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side
      effects.

      In this pilot study patients with membranous nephropathy and renal failure will be treated
      with mycophenolate mofetil and prednisone. The outcome will be compared with historical
      controls treated with a similar regimen containing cyclophosphamide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal function (serum creatinine)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>proteinuria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Glomerulonephritis, Membranous</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil orally 1000 mg twice a day (BID)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone 0,5 mg/kg orally on alternate days</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous (i.v.) methylprednisolone 1000 mg, total 9</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Membranous nephropathy

          -  Serum creatinine (Screat)&gt; 1,5 mg/dl or ECC &lt; 70 ml/min or increase Screat &gt; 50%

          -  Proteinuria &gt; 2 g/day

        Exclusion Criteria:

          -  Systemic diseases

          -  Pregnancy wish

          -  Active infection

          -  Liver dysfunction

          -  Abnormal hematology lab

          -  Unstable angina

          -  Nonsteroidal anti-inflammatory agents (NSAIDs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack F Wetzels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>December 5, 2005</last_update_submitted>
  <last_update_submitted_qc>December 5, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2005</last_update_posted>
  <keyword>membranous nephropathy</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

